

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 1, 2013**

---

**CORONADO BIOSCIENCES, INC.**  
(Exact Name of Registrant as Specified in Charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-35366**  
(Commission  
File Number)

**20-5157386**  
(IRS Employer  
Identification No.)

**24 New England Executive Park, Burlington, MA**  
(Address of Principal Executive Offices)

**01803**  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: (781) 652-4500**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 1.01. Entry into a Material Definitive Agreement.**

The information provided in Item 5.02(b) below is hereby incorporated by reference to this Item 1.01.

**Item 2.02. Results of Operations and Financial Condition.**

On August 5, 2013, Coronado Biosciences, Inc. issued a press release reporting unaudited financial results for the quarter ended June 30, 2013. A copy of the press release is attached hereto as Exhibit 99.1.

The information in Items 2.02 and 9.01 of this current report on Form 8-K (excluding Exhibit 10.51) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.**

(b) Effective August 1, 2013, Coronado and Dr. Hehenberger entered into an Amendment to Employment Agreement to appoint Dr. Hehenberger Coronado’s Executive Vice President of Scientific Affairs. Dr. Hehenberger previously served as Coronado’s Executive Vice President and Chief Medical Officer, from April 19, 2012 to July 31, 2013. The Amendment to Employment Agreement is attached hereto as Exhibit 10.51 and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
10.51	Amendment to Employment Agreement dated August 1, 2013 by and between Coronado Biosciences, Inc. and Dr. Karin Hehenberger, M.D., Ph.D.
99.1	Press release dated August 5, 2013.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORONADO BIOSCIENCES, INC.

Date: August 5, 2013

/s/ Dale Ritter

Name: Dale Ritter

Title: Senior Vice President, Finance

## AMENDMENT TO EMPLOYMENT AGREEMENT

This AMENDMENT TO EMPLOYMENT AGREEMENT ("Amendment") is dated August 1, 2013 by and between Coronado Biosciences, Inc., a Delaware corporation (the "Company"), and Karin Hehenberger, MD, PhD (the "Executive"). Unless the context otherwise requires, capitalized terms used herein shall have the meanings set forth in the Employment Agreement (as defined below) and in this Amendment.

WHEREAS, the Company and the Executive are parties to an Employment Agreement dated April 19, 2012 (the "Employment Agreement"); and

WHEREAS, the Company and the Executive desire to amend the Employment Agreement.

NOW THEREFORE, in consideration of the premises and the mutual promises set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows.

1. **Amendment One.** Subsection 1.1 is hereby deleted and replaced with the following:

"Executive's position shall be Executive Vice President of Scientific Affairs."

2. **Ratification.** Each of the Company and Executive agree that this Amendment and the change of title and duties do not constitute Good Reason under the Employment Agreement.

3. **Effect of Amendment.** Except as expressly amended herein, the terms of the Employment Agreement are incorporated herein by reference as if fully set out and shall remain in full force and effect in accordance with their terms.

IN WITNESS WHEREOF, the parties hereto have executed and delivered this Amendment to Employment Agreement as of the date and year first above written.

COMPANY:

**CORONADO BIOSCIENCES, INC.**

By: /s/ Harlan F. Weisman, M.D.

Name: Harlan F. Weisman, M.D.

Title: Chairman and CEO

EXECUTIVE:

/s/ Karin Hehenberger, M.D., PH.D.

**KARIN HEHENBERGER, M.D., PH.D.**



### **CORONADO BIOSCIENCES REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2013**

Burlington, MA – August 5, 2013 – Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today its financial results for the second quarter ended June 30, 2013.

“We have completed enrollment of 250 patients in our Phase 2 TRUST-I trial and remain on track to report top-line data in the fourth quarter of 2013,” said Dr. Harlan F. Weisman, Coronado’s Chairman and CEO. “The results of the TRUST-I trial will provide an abundance of data on TSO (*Trichuris suis* ova or CNDO-201) and the Hygiene Hypothesis, which we look forward to sharing with the medical and investment communities. A positive outcome would bring TSO one step closer to becoming an important treatment option for patients suffering from Crohn’s disease.”

“We have also further strengthened our financial position during this quarter,” continued Dr. Weisman. “From April 1, 2013 through August 2, 2013, we sold an aggregate of approximately 5.5 million shares of our common stock through our at-the-market sales facilities for net proceeds of approximately \$49.4 million, including 2.2 million shares of our common stock for net proceeds of approximately \$18.4 million since June 30, 2013.”

#### Financial Highlights:

- Coronado reported a net loss of \$10.7 million and \$19.5 million for the three and six months ended June 30, 2013, respectively, compared to a net loss of \$6.5 million and \$13.0 million for the three and six months ended June 30, 2012, respectively.
- Research and development expenses were \$7.8 million and \$13.8 million for the three and six months ended June 30, 2013, respectively, compared to \$4.5 million and \$9.1 million for the three and six months ended June 30, 2012, respectively. The increases in research and development expenses relate primarily to the TSO development program.
- General and administrative expenses were \$2.5 million and \$5.0 million for the three and six months ended June 30, 2013, respectively, compared to \$1.9 million and \$3.9 million for the three and six months ended June 30, 2012, respectively. The increases in general and administrative expenses included expenses primarily related to Coronado’s infrastructure growth to support increased business activity.
- At June 30, 2013, Coronado’s cash and cash equivalents totaled \$67.9 million. To date, Coronado has sold approximately 7.1 million shares under its at-the-market sales facilities for net proceeds of approximately \$61.2 million.

---

#### Other Corporate Highlights:

- Appointed Dr. George Avgerinos as Senior Vice President, Biologics Operations. Dr. Avgerinos leads Coronado's global manufacturing and supply chain efforts for both TSO and CNDO-109. Most recently, Dr. Avgerinos was at AbbVie, formerly Abbott Laboratories, where he was Vice President, HUMIRA® Manufacturing Sciences and External Partnerships.
- Appointed Dr. Karin Hehenberger as Executive Vice President of Scientific Affairs as of August 2013. Dr. Hehenberger previously served as our Executive Vice President & Chief Medical Officer from April 2012 through July 2013. Dr. Hehenberger leads Coronado's strategic efforts in developing novel indications for its products and serves as Coronado's scientific communications spokesperson.

#### Upcoming Events:

- Wedbush 2013 Life Sciences Management Access Conference, August 13, 2013
- Canaccord Genuity 33<sup>rd</sup> Annual Growth Conference, August 14, 2013

#### *Conference Call and Webcast Information*

Coronado management will review its second quarter financial results and development programs via conference call and webcast today at 8:30 AM ET. To participate in the conference call, please dial (877) 312-5413 (toll free from the US and Canada), or (253) 237-1511 (for international callers). Investors may also access a live audio webcast of the call at [www.coronadobiosciences.com](http://www.coronadobiosciences.com) on the Events & Webcasts page.

A replay of the webcast will be available shortly after the conclusion of the call. The webcast archive will remain available for one year. An audio replay will also be available shortly after the conclusion of the call and will be made available until August 12, 2013. The audio replay can be accessed by dialing (855) 859-2056 (toll free from the US and Canada), or (404) 537-3406 (for international callers) and entering Event ID 22772111.

#### **About Coronado Biosciences**

Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The company's two principal pharmaceutical product candidates in clinical development are: TSO (*Trichuris suis* ova or CNDO-201), a biologic for the treatment of autoimmune diseases, including Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML), multiple myeloma and solid tumors. For more information, please visit [www.coronadobiosciences.com](http://www.coronadobiosciences.com).

#### **Forward-Looking Statements**

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the company's product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: our ability to attract, integrate and retain key personnel; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; our dependence on third party suppliers; and competition; as well as other risks described in our SEC filings.

---

We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

**Contact:**

Lucy Lu, MD, Executive Vice President & Chief Financial Officer  
Coronado Biosciences, Inc.  
781-652-4525; [ir@coronadobio.com](mailto:ir@coronadobio.com)

Marcy Nanus, Vice President  
The Trout Group, LLC.  
646-378-2927; [mnanus@troutgroup.com](mailto:mnanus@troutgroup.com)

Susan Forman  
Dian Griesel Inc.  
212-825-3210; [susan@dgicomm.com](mailto:susan@dgicomm.com)

---

**CORONADO BIOSCIENCES, INC. AND SUBSIDIARY**

(A development stage enterprise)

**Consolidated Balance Sheets**

(\$ in thousands)

(Unaudited)

	June 30, 2013	December 31, 2012
<b>ASSETS</b>		
Cash and cash equivalents	\$67,886	\$ 40,199
Prepaid and other current assets	243	393
Total current assets	68,129	40,592
Property & equipment net	535	51
Other	114	349
Total Assets	<u>\$68,778</u>	<u>\$ 40,992</u>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current liabilities	\$ 8,953	\$ 5,132
Note payable, non-current	9,760	12,386
Other long-term liabilities	1,507	1,441
Total Liabilities	20,220	18,959
Stockholders' Equity	<u>48,558</u>	<u>22,033</u>
Total Liabilities and Stockholders' Equity	<u>\$68,778</u>	<u>\$ 40,992</u>



**CORONADO BIOSCIENCES, INC. AND SUBSIDIARY**

(A development stage enterprise)

**Consolidated Statements of Operations**

**(\$ in thousands except for share amounts)**

**(Unaudited)**

	For the three months ended June 30,		For the six months ended June 30,	
	2013	2012	2013	2012
<b>Operating expenses:</b>				
Research and development	\$ 7,795	\$ 4,525	\$ 13,769	\$ 9,116
General and administrative	2,499	1,940	4,983	3,930
Loss from operations	(10,294)	(6,465)	(18,752)	(13,046)
Interest income	109	29	185	73
Interest expense	(485)	(19)	(961)	(38)
Net loss attributed to Common Stockholders	<u>(\$ 10,670)</u>	<u>(\$ 6,455)</u>	<u>(\$ 19,528)</u>	<u>(\$ 13,011)</u>
Basic and diluted net loss per common share	<u>(\$ 0.38)</u>	<u>(\$ 0.34)</u>	<u>(\$ 0.73)</u>	<u>(\$ 0.69)</u>
Weighted average common shares outstanding—basic and diluted	<u>28,095,522</u>	<u>19,194,053</u>	<u>26,646,993</u>	<u>18,899,149</u>